关于沙特FDA监管经验与智能GxP检查的反思
Ali M Alhomaidan1, Nawaf G Al-Murikhi2, Morae A Al-Qarni2
1Saudi Food and Drug Authority Riyadh, Riyadh, Saudi Arabia. ahomaidan@sfda.gov.sa.
Therapeutic innovation & regulatory science
|April 10, 2024
概括
智能GxP检查为监管合规性评估提供了有效的远程替代方案,证明了文档评估的高准确性. 这些智能检查提供了一种有价值的解决方案,可以在充满挑战的时期保持监督.
科学领域:
- 监管科学 监管科学
- 制药技术 制药技术 制药技术
- 医疗器械的合规性 医疗器械的合规性
背景情况:
- 由于COVID-19的流行,监管检查需要远程解决方案.
- 智能GxP检查是由SFDA开发的,用于远程合规评估.
- 这些检查利用技术,如视频直播,以提高效率.
研究的目的:
- 检查SFDA在2020-2022年间的远程检查经验.
- 在智能检查中评估文档评估的准确性.
- 评估智能GxP检查目标的实现程度.
主要方法:
- 分析SFDA的智能检查报告 (2020-2022年).
- 包括来自不同部门的数据:医疗器械,制药,食品制造等.
- 评估重点是文档的准确性和目标的实现.
主要成果:
- 智能GxP检查在实现访问目标方面被证明是有效的.
- 在文件评估中观察到高度的准确性.
- 这些远程检查在疫情期间是一个切实可行的替代方案.
结论:
- 智能GxP检查是传统现场检查方法的宝贵补充.
- 虽然有效,但它们不能完全取代传统的现场检查.
- 确定了当前远程评估技术的局限性.
相关概念视频
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)